543220 Share Price Performance
₹1,053.70
31.55 (3.09%)
17.5% overvalued intrinsic discount
₹896.53
Fair Value
Price ₹1,053.70
AnalystLowTarget ₹896.53
AnalystHighTarget ₹1,500.00
AnalystConsensusTarget ₹1,264.42
Fair Value₹896.53
Share Pricen/a
Max Healthcare Institute Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
543220 Community Narratives
AN
Fair Value ₹896.53 17.5% overvalued intrinsic discount
Northern India Risks And Rising Capex Will Burden Future Operations
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value ₹1.5k 29.8% undervalued intrinsic discount
Rising Disposable Incomes And Aging Populations Will Drive Healthcare Demand
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value ₹1.26k 16.7% undervalued intrinsic discount
Expanding Premium Healthcare In India Will Meet Rising Demand
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
Northern India Risks And Rising Capex Will Burden Future Operations
Key Takeaways Concentration of assets in Northern India and expansion plans raise exposure to regional risks and operational financial strain if new investments underperform. Increased dependence on specialized services and regulatory pressures may suppress pricing power and reduce long-term revenue growth from core hospital operations.Read more
17
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
₹896.53
17.5% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
20.12% p.a.
Profit Margin
16.63%
Future PE
52.54x
Price in 2029
₹1.28k
Rising Disposable Incomes And Aging Populations Will Drive Healthcare Demand
Key Takeaways Rapid ramp-up of new beds and digital integration of acquisitions will drive stronger-than-expected revenue, margin expansion, and returns across the network. Expansion into super-specialties and adjunct businesses, combined with rising urban healthcare demand, positions the company for sustained premium growth and profitability.Read more
20
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
₹1.5k
29.8% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
41.23% p.a.
Profit Margin
18.84%
Future PE
47.74x
Price in 2029
₹2.13k
Expanding Premium Healthcare In India Will Meet Rising Demand
Key Takeaways Expansion in bed capacity and integration of acquisitions will drive sustained revenue and profit growth, leveraging increasing demand for premium healthcare services. Growth in high-value specialties, digital engagement, and broader health insurance access will boost margins, enhance patient retention, and support long-term volume stability.Read more
68
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
₹1.26k
16.7% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
30.36% p.a.
Profit Margin
17.86%
Future PE
57.82x
Price in 2029
₹1.82k
Trending Discussion
Recently Updated Narratives
AN
543220: Lower Fair Value And Margin Assumptions Will Pressure Future Returns
Fair Value: ₹896.53 17.5% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
543220: Upcoming Board Decisions On Expansion Will Support Stronger Long-Term Upside Potential
Fair Value: ₹1.5k 29.8% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
543220: Upcoming Acquisition Plans Will Support Continued Upside Ahead
Fair Value: ₹1.26k 16.7% undervalued intrinsic discount
8 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Max Healthcare Institute Limited Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- 14.58
- 62.01%
- 17.43%
- 32.6%
About 543220
- Founded
- 2001
- Employees
- 15114
- CEO
- WebsiteView website
Max Healthcare Institute Limited provides medical and healthcare services in India. It offers services in various specialties, including cardiac sciences, orthopedics, oncology, renal sciences, neurosciences, minimal access and general surgery, pulmonology, obstetrics, gynecology, pediatrics, and nephrology, liver and biliary sciences, gastroenterology and Gi surgery, plastic and reconstructive surgery, and organ transplants, as well as ear, nose, and throat. The company also provides Max@Home, a platform that offers health and wellness services at home; and MaxLab, which provides diagnostic services to patients outside its network of hospitals through various channels comprising third-party hospital laboratory management. It operates through a network of healthcare facilities, including hospitals and medical centres. The company was incorporated in 2001 and is based in Gurugram, India.